Clinical Trial Update: 506U78 in Treating Patients With Refractory Hematologic Cancer [Phase 2]

View source ↗

Summary

This entry notes the completion of a Phase 2 trial of 506U78 in relapsed pediatric hematologic cancers, including recurrent childhood acute lymphoblastic leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Acute Lymphoblastic Leukemia
• Childhood Lymphoblastic Lymphoma
• T-cell Childhood Acute Lymphoblastic Leukemia

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma | Phase 2 | Status: COMPLETED